Chardan initiated coverage of Pharma Mar with a Buy rating and EUR 60 price target. The analyst cites the potential of the company’s lead commercial drug, Zepzelca targeting small cell lung cancer, to obtain additional regulatory approvals, significantly increasing its addressable market for the Buy rating.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHMMF: